Sprint Bioscience AB (publ) (FRA:5JA1)

Market Cap	16.28M +74.4%
Revenue (ttm)	4.52M -18.6%
Net Income	-2.32M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	1.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	50
Open	0.1175
Previous Close	0.1195
Day's Range	0.1175 - 0.1175
52-Week Range	0.0174 - 0.1660
Beta	n/a
RSI	57.79
Earnings Date	Feb 12, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 29
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5JA1

Financial Performance

In 2024, Sprint Bioscience AB's revenue was 66.14 million, an increase of 27.97% compared to the previous year's 51.69 million. Losses were -18.28 million, 4072.8% more than in 2023.

Financial numbers in SEK